Physician profile
Alan K Gruskin
NPI 1174586515
$7,666.19
in general payments reported to CMS, 2019-2025
28 companies · $798 in 2025
The $798 reported for 2025 was more than what a typical Pain Medicine (Physical Medicine & Rehabilitation) provider received nationally (typical 2025 total: $400).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $439 · 2020: $518 · 2021: $1,098 · 2022: $3,153 · 2023: $808 · 2024: $852 · 2025: $798.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,459.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,458.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,186.45 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,198.29 | 2019-2025 | Relistor |
| Forte Bio-Pharma LLC | $1,117.71 | 2020-2025 | Prolate, Nalocet, Tanlor |
| Collegium Pharmaceutical, INC. | $441.15 | 2019-2024 | Xtampza |
| Pfizer INC. | $368.26 | 2020-2025 | |
| Valinor Pharma, LLC | $234.08 | 2023-2024 | Movantik |
| Biohaven Pharmaceutical Holding Company LTD. | $163.01 | 2022 | |
| Virtus Pharmaceuticals LLC | $162.08 | 2021 | |
| Redhill Biopharma INC. | $147.90 | 2020-2022 | |
| Lilly USA, LLC | $85.69 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $82.73 | 2021 | |
| Biodelivery Sciences International, INC. | $82.43 | 2020-2021 | |
| Axsome Therapeutics, INC. | $61.16 | 2025 | Symbravo |
| Allergan, INC. | $45.59 | 2020 | |
| Idorsia Pharmaceuticals US INC | $38.67 | 2023-2025 | Quviviq, Quviviq |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Protega Pharmaceutials INC | $35.44 | 2025 | Roxybond |
| Emd Serono, INC. | $24.58 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $23.38 | 2019 | |
| Alnylam Pharmaceuticals INC. | $22.03 | 2023 | Givlaari |
| Novartis Pharmaceuticals Corporation | $20.26 | 2019 | |
| Depuy Synthes Sales INC. | $18.72 | 2019 | |
| West Therapeutics Development, LLC | $17.86 | 2020 | |
| Scilex Pharmaceuticals INC. | $17.81 | 2019 | |
| Averitas Pharma INC. | $16.83 | 2023 | Qutenza |
| Kaleo, INC. | $14.07 | 2019 | |
| Hikma Pharmaceuticals USA | $13.90 | 2022 | |
| Sentynl Therapeutics, INC. | $13.89 | 2019 | |
| Eisai INC. | $12.22 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Gruskin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.